SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-299029"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-299029" > Impact of glycoprot...

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes : Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Shimada, Yuichi J. (författare)
Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA.;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.;Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
Bansilal, Sameer (författare)
Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA.
Wiviott, Stephen D. (författare)
Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
visa fler...
Becker, Richard C. (författare)
Univ Cincinnati, Coll Med, Heart Lung & Vasc Inst, Div Cardiovasc Hlth & Dis, Cincinnati, OH USA.
Harrington, Robert A. (författare)
Stanford Univ, Dept Med, Stanford, CA 94305 USA.
Himmelmann, Anders (författare)
AstraZeneca Res & Dev, Molndal, Sweden.
Neely, Benjamin (författare)
Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
Husted, Steen (författare)
Hosp Unit West, Med Dept, Herning Holstebro, Denmark.
James, Stefan K. (författare)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Katus, Hugo A. (författare)
Univ Klinikum Heidelberg, Med Klin, Heidelberg, Germany.
Lopes, Renato D. (författare)
Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
Steg, Ph. Gabriel (författare)
INSERM, U1148, Paris, France.;Hop Bichat Claude Bernard, Dept Hosp Univ FIRE, AP HP, F-75877 Paris, France.;Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.;NHLI Imperial Coll, Royal Brompton Hosp, ICMS, London, England.
Storey, Robert F. (författare)
Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
Wallentin, Lars (författare)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Cannon, Christopher P. (författare)
Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA.;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
visa färre...
Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.;Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA. (creator_code:org_t)
Elsevier BV, 2016
2016
Engelska.
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 177, s. 1-8
Relaterad länk:
https://doi.org/10.1...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding. We evaluated whether the use of glycoprotein IIb/IIIa inhibitor (GPI) impacts the relative efficacy and safety of ticagrelor compared with clopidogrel. Methods PLATO randomized 18,624 subjects with acute coronary syndrome to ticagrelor versus clopidogrel. The primary efficacy end point was cardiovascular death/myocardial infarction/stroke, and the primary safety end point was major bleeding. The use of GPI was at the physician's discretion and open-label. We evaluated outcomes at 30 days stratified by GPI use in the subgroup of 9,983 patients who underwent percutaneous coronary intervention (PCI) within 72 hours. Results A total of 4,020 (40%) received a GPI. Those receiving a GPI were more likely to be younger, be male, and undergo multivessel PCI. There was no interaction between treatment and GPI use for the primary efficacy and safety end points. Patients treated without GPI had a lower rate of definite stent thrombosis and higher rate of minor/major bleeding with ticagrelor compared with clopidogrel (P<.05), whereas there was no such difference with GPI (P interaction <.05). Conclusions In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Uppsala universitet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy